Evaxion Biotech ( (EVAX) ) has provided an update.
On March 4, 2025, Evaxion Biotech announced its participation in several upcoming investor and scientific conferences across the US and Europe. These conferences, scheduled from March to June 2025, will allow Evaxion to provide company and scientific updates, engage with stakeholders, and explore potential business and scientific collaborations. This strategic move aims to enhance Evaxion’s industry positioning and foster partnerships that could drive future growth and innovation.
More about Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage TechBio company based in Denmark, specializing in developing vaccines powered by its AI-Immunology™ platform. The company focuses on creating novel immunotherapies for cancer, bacterial diseases, and viral infections, with a pipeline that includes clinical-stage oncology vaccines and preclinical infectious disease treatments.
YTD Price Performance: -54.14%
Average Trading Volume: 2,513,597
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.28M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com